VAXCYTE Hires Ex-Pfizer Vaccine Chief, Narrows VAX-31 Data Timing

Vaxcyte named Luis Jodar CMO and David McAvoy CLO, and now expects OPUS-1 Phase 3 topline data by the end of October 2026.

Share
Vaxcyte is preparing for topline data from its 31-valent pneumococcal conjugate vaccine candidate.